Skip to main content
Clinical Trials/NCT03584594
NCT03584594CompletedNot Applicable

Prepepsin, the Improvement of the Early Inflammatory Biomarkers Strategy for the Diagnostics of Sepsis in Critically Ill Patients

University Hospital Ostrava2 sites in 1 country200 target enrollmentStarted: June 1, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
200
Locations
2
Primary Endpoint
Serum concentration of Presepsin

Study Overview

Brief Summary

Sepsis is one of the most common causes of death worldwide. It is caused by a complex of inadequate host responses to infection. Sepsis remains a major challenge of modern intensive care medicine. Despite recent improvements, the incidence of sepsis in critically ill patients increases steadily (25%) and mortality rates remain unacceptably high (30%). It is difficult to distinguish the sepsis from the non-infectious systemic inflammatory response syndrome. Early identification of the origin of infection can help dramatically to improve outcome and reduce mortality. That is why clinicians need fast, reliable and specific biomarkers for sepsis recognition.

Detailed Description

Comparison between the detection of novel early inflammatory biomarker (PSEP) and the others normally used biomarkers (c-reactive protein - CRP, interleukin 6 - IL6, procalcitonin - PCT) in the early diagnosing of sepsis in the critically ill patients A broad range of clinical and laboratory parameters are combined (Surviving sepsis campaign, international guidelines) for early sepsis identification: white blood cells (WBC), C-reactive protein (CRP), interleukin 6 (IL-6), procalcitonin (PCT).

An ideal biomarker should be a fast and specific increase in sepsis, short half-life, rapid decrease after administration of an effective therapy and fast (bed-side) method of determination. None of the current biomarkers have all of these characteristics.

We investigate the diagnostic accuracy of presepsin compared to other biomarkers (WBC, PCT, IL6, CRP) for infection or sepsis, defined according to Sepsis-3 definition (Singer, JAMA 2016) in adult patients admitted to ICU with suspected sepsis.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • signed informed consent
  • diagnosis of sepsis from qSOFA (quick Subsequent Organ Failures Assessment)
  • need of vasopressors for mean arterial pressure (MAP) ≥ 65 mmHg
  • lactate levels ≥ 2mmol/l despite adequate volume resuscitation

Exclusion Criteria

  • age below 18 years
  • terminal state of disease
  • pregnancy

Outcomes

Primary Outcomes

Serum concentration of Presepsin

Time Frame: 47 months

Serum concentration of Presepsin in patients with sepsis or septic shock will be compared to PCT, IL6 and CRP results.

Area under the Receiver-operating characteristic Curve

Time Frame: 47 months

Area under the Receiver-operating characteristic Curve (ROC-AUC) of the presepsin and other biomarkers (PCT, IL6, CRP) for diagnostic value of any biomarker will be analysed on a scale 0-100.

Secondary Outcomes

  • Correlation of serum concentration of presepsin with detection of microbial agents(47 months)

Investigators

Sponsor
University Hospital Ostrava
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials